Zobrazeno 41 - 50
of 264
pro vyhledávání: '"Aaron P. Rapoport"'
Autor:
Kirk Cahill, James Godfrey, Chadi Nabhan, Theodore G. Karrison, Jessica Robertson, Justin Kline, Kenneth S. Cohen, Michael R. Bishop, Walter M. Stadler, Reem Karmali, Parameswaran Venugopal, Seo-Hyun Kim, Aaron P. Rapoport, Sonali M. Smith
Publikováno v:
Blood. 140:6594-6595
Autor:
David Tong Chen, Olga Goloubeva, Hanan Alkhaldi, Aaron P. Rapoport, Saurabh Dahiya, Nancy M. Hardy, Djordje Atanackovic, Mehmet Hakan Kocoglu, Forat Lutfi, Jean A. Yared
Publikováno v:
Blood. 140:9526-9527
Autor:
Giulia Cheloni, Dimitra Karagkouni, Daniela Torres, David J. Chung, Nina Shah, Natalie S. Callander, Thinle Chodon, Yvonne Efebera, Nancy Geller, Peiman Hematti, Hillard Lazarus, Ehsan Malek, Philip L. McCarthy, Ajay K. Nooka, Jacalyn Rosenblatt, Aaron P. Rapoport, Robert J. Soiffer, Dina Stroopinsky, Edmund K. Waller, Marcelo C. Pasquini, Ioannis Vlachos, David Avigan
Publikováno v:
Cancer Research. 83:6785-6785
Introduction: Multiple myeloma (MM), a clonal disorder of terminally differentiated plasma cells, is the second most common hematologic malignancy with ~57.9% 5-year survival rate. Current MM therapies are not curative and in most patients MM relapse
Autor:
Jawad Malik, Saurabh Dahiya, Gabriela Sanchez-Petitto, Preeti Chandra, A. Haririan, Matthew R. Weir, Aaron P. Rapoport, Cinthia B. Drachenberg, Jonathan Bolanos
Publikováno v:
Clinical Nephrology. Case Studies
Use of granulocyte colony-stimulating factor (G-CSF) has been associated with side effects including reports of acute glomerulonephritis (GN), almost all of which have been immune complex associated. There is one prior report of pauci-immune GN in a
Autor:
Abhinav Deol, Amanda F. Cashen, N. Nora Bennani, Khoan Vu, Michael D. Jain, David B. Miklos, Sattva S. Neelapu, Brian T. Hill, Jason R. Westin, Julie M. Vose, Alison R. Sehgal, Julio C. Chavez, Aaron P. Rapoport, Lazaros J. Lekakis, Andre Goy, Patrick M. Reagan, Javier Munoz, Joseph P. McGuirk, Loretta J. Nastoupil, Lei Feng, Olalekan O. Oluwole, Saurabh Dahiya, Jay Y. Spiegel, Frederick L. Locke, Charalambos Andreadis, Yi Lin, Matthew A. Lunning, Armin Ghobadi
Publikováno v:
J Clin Oncol
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 38, iss 27
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 38, iss 27
PURPOSE Axicabtagene ciloleucel (axi-cel) is an autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory large B-cell lymphoma (LBCL) on the basis of the single-arm phase II ZUMA-1 trial, which showed b
Autor:
Jean A. Yared, Elizabeth Hutnick, Ashraf Badros, Mehmet H. Kocoglu, Nancy M. Hardy, Forat Lutfi, Søren M. Bentzen, Jonathan Siglin, Aaron P. Rapoport, Firas El Chaer, Carl Shanholtz, Kathleen Ruehle, Vivek Kesari, Noa G. Holtzman, Hao Xie, Haroon Ahmad, Saurabh Dahiya, Ali Bukhari, Natalie Gahres
Publikováno v:
Neuro Oncol
Background CD19-directed chimeric antigen receptor (CAR) T-cell therapy (CAR-T) has emerged as effective for relapsed/refractory large B-cell lymphoma (R/R LBCL). The neurologic toxicity seen with CAR-T, referred to as immune effector cell–associat
Autor:
Kapil K. Saharia, Jennifer S. Husson, Silke V. Niederhaus, Thierry Iraguha, Stephanie V. Avila, Youngchae J. Yoo, Nancy M. Hardy, Xiaoxuan Fan, Destiny Omili, Alice Crane, Amber Carrier, Wen Y. Xie, Erica Vander Mause, Kim Hankey, Sheri Bauman, Patricia Lesho, Heather D. Mannuel, Ashish Ahuja, Minu Mathew, James Avruch, John Baddley, Olga Goloubeva, Kirti Shetty, Saurabh Dahiya, Aaron P. Rapoport, Tim Luetkens, Djordje Atanackovic
BackgroundSolid organ transplant recipients (SOTR), who typically receive post-transplant immunosuppression, show increased COVID-19-related mortality. It is unclear whether an additional dose of COVID-19 vaccines in SOTR can overcome the reduced imm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fa251084972f92af72b7f43c264d059d
https://doi.org/10.1101/2021.12.29.21268529
https://doi.org/10.1101/2021.12.29.21268529
Autor:
Aisha A Mumtaz, Andrew Fischer, Forat Lutfi, Lisa R Matsumoto, Djordje Atanackovic, Elif T Kolanci, Kim G Hankey, Nancy M Hardy, Jean A Yared, Mehmet H Kocoglu, Aaron P Rapoport, Saurabh Dahiya, Albert S Li, Sarah Brem Sunshine
Publikováno v:
The British journal of ophthalmology.
Background/aimsChimeric antigen receptor T-cell (CAR T) therapy has been shown to improve the remission rate and survival for patients with refractory haematological malignancies. The aim of this study is to describe ocular adverse effects associated
Autor:
Michael L. Olson, Erica R. Vander Mause, Sabarinath V. Radhakrishnan, Joshua D. Brody, Aaron P. Rapoport, Alana L. Welm, Djordje Atanackovic, Tim Luetkens
Chimeric antigen receptor (CAR) T cells using the high-affinity CD19 binding domain FMC63 are an effective treatment for patients with relapsed and aggressive B cell lymphoma. However, antigen loss and poor CAR T cell persistence remain common causes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::361b9b8a802216864d183299ffac2bcd
https://doi.org/10.1101/2021.12.05.471117
https://doi.org/10.1101/2021.12.05.471117
Autor:
Joseph A. Fraietta, Edward A. Stadtmauer, Aaron P. Rapoport, Bruce L. Levine, Wei-Ting Hwang, Dan T. Vogl, Adam D. Cohen, Megan M. Davis, Carl H. June, Adam Waxman, Don L. Siegel, Alfred L. Garfall, Michael C. Milone, Ehren K. Dancy, J. Joseph Melenhorst
Publikováno v:
Blood Advances. 3:2812-2815
Key points T cells from patients early in myeloma therapy exhibit better fitness for CAR T manufacturing than those from relapsed/refractory patients. CAR T cells may be more effective if manufactured from patients before onset of relapsed/refractory